Why Two Wall Street Titans Love BioMarin Pharma

By: via Benzinga
In a report published Tuesday, Piper Jaffray analyst Joshua E. Schimmer maintained an Overweight rating on BioMarin Pharmaceutical Inc ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.